Your session is about to expire
← Back to Search
Tirzepatide for Type 2 Diabetes (SURPASS-SWITCH Trial)
SURPASS-SWITCH Trial Summary
This trial is testing whether a different diabetes medication is more effective and has fewer side effects than increasing the dose of the current medication.
SURPASS-SWITCH Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSURPASS-SWITCH Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 210 Patients • NCT05024032SURPASS-SWITCH Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of pancreatitis.You have type 1 diabetes.I have type 2 diabetes.I have a serious diabetic eye condition needing immediate treatment.I had to lower my dulaglutide dose because it was too harsh, and couldn't increase it again.I have severe heart failure that limits my daily activities.My kidney function is significantly reduced.I have a history of medullary thyroid cancer or MEN2 in my family or myself.I have used weight loss medications in the last 90 days.I haven't taken, or have been on a stable dose of up to 3 diabetes medications for 3 months.I have been taking a stable dose of dulaglutide weekly for at least 6 months.I have been taking a stable dose of dulaglutide weekly for at least 6 months.I have been on insulin before, except for pregnancy diabetes or short-term acute conditions.I have not had a heart attack, stroke, or heart failure hospitalization in the last 2 months.I have type 2 diabetes.You weigh more than what is considered healthy for your height.Your HbA1c level is between 7.0% and 9.5%.Your weight has stayed about the same for the past 90 days.
- Group 1: Tirzepatide
- Group 2: Dulaglutide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many venues are actively conducting this experiment?
"Clinvest Research LLC in Springfield, Missouri, Metabolic Research Institute, Inc. in West Palm Beach, Florida and NorthShore University Health System in Skokie, Illinois are all sites observing this trial with an additional 10 locations also recruiting patients."
Are there opportunities to become involved in this research project currently available?
"The clinical trial hosted on clinicaltrials.gov is not currently enrolling participants; the protocol was initially posted on December 8th 2022 and last edited November 23rd, 2022. However, there are 1,440 trials actively searching for candidates at this moment."
Has the FDA sanctioned Tirzepatide for medicinal use?
"Thanks to the completion of a Phase 4 trial, Tirzepatide was deemed safe and given a score 3 out of 3."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger